Inflammatory bowel disease induced by secukinumab
10.3760/cma.j.cn114015-20221008-00922
- VernacularTitle:司库奇尤单抗诱发炎性肠病
- Author:
Guiying WU
1
;
Hongbin LI
1
;
Ning TIE
1
;
Lijie BAI
1
;
Yong WANG
1
Author Information
1. 内蒙古医科大学附属医院风湿免疫科，呼和浩特 010059
- Publication Type:Journal Article
- Keywords:
Bowel disease, inflammatory;
Psoriasis;
Secukinumab;
Interleukin-17A inhibitors;
Adverse drug reactions
- From:
Adverse Drug Reactions Journal
2023;25(9):574-576
- CountryChina
- Language:Chinese
-
Abstract:
A 34-year-old male patient received a subcutaneous injection of 300 mg of secukinumab once a week for 5 times, subsequently 300 mg once every 4 weeks for 3 times because of psoriasis. Then the patient developed bloody purulent stool. Electronic colonoscopy revealed diffuse mucosal congestion and edema in the sigmoid colon at a distance of 25 cm from the anus. The pathological examination results of tissue biopsy showed severe chronic inflammation, erosion, and shallow ulcer formationin the sigmoid colon. Inflammatory bowel disease caused by secukinumab was considered. Then the drug was stopped, and mesalazine enema solution 60 g once daily was given. After half a month of treatment, the patient′s bloody purulent stool was improved significantly, and after 2 months, it disappeared. Electronic colonoscopy showed that the mucosa of the sigmoid colon was rough, granular, and scattered with small patches of bleeding at a distance of 20 cm to 25 cm from the anus, which was diagnosed as having ulcerative colitis (in remission). Mesalazine enema was discontinued and changed to mesalazine suppository 0.5 g once daily.
